Rheumatism News and Research

RSS

Rheumatism is a group of disorders marked by inflammation or pain in the connective tissue structures of the body. These structures include bone, cartilage, and fat.

New criteria by ACR for early diagnosis, treatment of rheumatoid arthritis

New criteria for rheumatoid arthritis (RA), published in the Annals of Rheumatic Diseases, could prevent thousands of people from developing disabling late stage disease, by redefining how RA should be classified.Rheumatoid arthritis is a progressive autoimmune inflammatory disease, primarily of the joints. If untreated, it leads to damage of bone and cartilage, joint deformities and disability. Around 350,000 people in the UK are living with RA, which affects around three times as many women as men.

13 Aug 2010

ACR announces revised classification criteria for rheumatoid arthritis

The American College of Rheumatology announced the release of revised classification criteria (created in collaboration with the European League Against Rheumatism) for rheumatoid arthritis, which will allow the study of treatments for RA at much earlier stages of the disease—before joint damage occurs—ultimately leading to better patient outcomes.

11 Aug 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2010.

7 Aug 2010

Study identifies options for restoring knee cartilage lubrication to prevent OA

An injury to the anterior cruciate ligament is fairly common, especially among young athletes. While it can often be corrected through surgery, the injury can lead to increased risk of developing degenerative joint diseases, including osteoarthritis. The problem is that fluid in the knee joint, which lubricates the cartilage, is impacted by the trauma of the injury and begins to deteriorate.

6 Aug 2010

FDA designates XOMA 052 orphan drug for Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

5 Aug 2010

Savient second-quarter net loss decreases to $5.0 million

Savient Pharmaceuticals, Inc. reported financial results for the three and six months ended June 30, 2010. The net loss for the second quarter of 2010 was $5.0 million, or $0.07 per basic and diluted share, on total revenues of $1.0 million, compared with a net loss of $54.8 million, or $0.92 per basic and diluted share on total revenues of $0.7 million for the second quarter of 2009.

4 Aug 2010

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

A recent study from researchers at Massachusetts General Hospital and University of Michigan provides the first direct evidence of linkage between elevated intrinsic (resting-state) brain connectivity and spontaneous pain intensity in patients with fibromyalgia (FM). This research shows an interaction of multiple brain networks, offering greater understanding of how pain arises. Details of the study appear online and in the August issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

30 Jul 2010

Immunosuppressive properties of TNF blockers may increase risk of malignancy in children

The Food and Drug Administration (FDA) received reports of malignancies in children using tumor necrosis factor (TNF) blockers, raising concerns of an associated risk and prompting an investigation. Researchers from the FDA set out to identify all reports of malignancy in children using infliximab, etanercept, and adalimumab and their report is published in the August issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

30 Jul 2010

Resting brain activity associated with spontaneous fibromyalgia pain

29 Jul 2010

TNF blockers may increase the risk of malignancy in children

The Food and Drug Administration (FDA) received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation.

29 Jul 2010

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease. Positive opinions are submitted to the European Commission for decision and are generally adopted within 30 days of receipt.

29 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

Human Genome Sciences second-quarter revenues increase to $38.8 million

Human Genome Sciences, Inc. today announced financial results for the quarter ended June 30, 2010, and provided highlights of recent key developments.

23 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

Phase II trial results of TB-402 presented at International Congress on Thrombosis

BioInvent International AB and ThromboGenics NV announce that the positive results from a Phase II trial of TB-402 (Anti-Factor VIII antibody) were presented at the 21st International Congress on Thrombosis in Milan, Italy yesterday. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

9 Jul 2010

Research findings link some autoimmune disorders with cancer

Patients with a certain type of scleroderma may get cancer and scleroderma simultaneously, Johns Hopkins researchers have found, suggesting that in some diseases, autoimmunity and cancer may be linked.

8 Jul 2010

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

An immune cell known to cause chronic inflammation in autoimmune disorders has been identified as a possible culprit in low back pain associated with herniated discs, according to doctors at Duke University Medical Center.

29 Jun 2010

Cartilage loss plays a role in development of OA, study says

A recent study determined that bone area predicted the development of medial (inner side) and lateral (outer side) knee cartilage damage and loss of medial cartilage volume. Subchondral bone mineral density (BMD) was associated with medial defect development but not cartilage loss. Researchers believe subchondral bone changes and loss of cartilage contribute to the development of osteoarthritis (OA).

28 Jun 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Human Genome Sciences, Inc. today announced the presentation of additional results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Vancouver at the 9th International Congress on Systemic Lupus Erythematosus on Friday and Saturday, June 25-26.

28 Jun 2010

Rheumatism News and Research

Further Reading

New criteria by ACR for early diagnosis, treatment of rheumatoid arthritis

ACR announces revised classification criteria for rheumatoid arthritis

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Study identifies options for restoring knee cartilage lubrication to prevent OA

FDA designates XOMA 052 orphan drug for Behcet's disease

Savient second-quarter net loss decreases to $5.0 million

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

Immunosuppressive properties of TNF blockers may increase risk of malignancy in children

Resting brain activity associated with spontaneous fibromyalgia pain

TNF blockers may increase the risk of malignancy in children

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

Regeneron second-quarter total revenues increase to $115.9 million

Human Genome Sciences second-quarter revenues increase to $38.8 million

NIH awards MacroGenics $9.8 million grant for three projects

Phase II trial results of TB-402 presented at International Congress on Thrombosis

Research findings link some autoimmune disorders with cancer

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

Cartilage loss plays a role in development of OA, study says

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Improving healthcare sustainability through carbon data

Latest News